Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E
Gastroesophageal Junction Adenocarcinoma
Explore 110 assets in Gastroesophageal Junction Adenocarcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Shanghai Miracogen Inc.
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04492488CT.gov A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Junction Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E (this asset) | Shanghai Miracogen Inc. | P1/2 | CCC · 48 |
| Irinotecan | AstraZeneca | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Oxaliplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Levofolinic Acid | Merck Sharp & Dohme LLC | P3 | BB |
| Disitamab Vedotin | BeOne Medicines | P2 | BB |
+42 more in the Gastroesophageal Junction Adenocarcinoma cohort
Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2/3 | B · 57 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
| Breast Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E in Gastroesophageal Junction Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-erbb2-receptor-tyrosine-protein-kinase-erbb-2-epidermal-growth-factor-receptor-2-egfr2-her2-her-2-p185c-erbb2-neu-cd340-humanized-monoclonal-antibody-conjugated-to-auristatin-e-gastroesophageal-junction-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →